Current genetically engineered mouse models capture only a small fraction of the genetic lesions that drive human cancer. Although CRISPR–Cas9 models have expanded this fraction, they are limited by their reliance on error-prone DNA repair.
In a recent paper published in nature biotechnology, Tyler Jacks and David Liu describe a prime editor mouse to model a broad spectrum of somatic mutations in vivo
Comments
Post a Comment